Sergeev P V, Stankov V I, Belykh A G, Saksonov N P, Volkov A F
Farmakol Toksikol. 1979 Jul-Aug;42(4):383-9.
The dynamics of distribution of 125I- and 131I-bilignost in intact rats has been studied in experimental pathological condition of the liver. It has been shown that the cholecystographic radiographic contrast agent (RCA) bilignost is absorbed and accumulated mainly by the liver. This indicates that the preparation elicits a selective action with respect to the liver. Administration of 125I-bilignost in conjunction with the unlabeled cholecystographic agents bilignost and endografin induces competition for absorption by the liver, which distinguishes these preparations from the urographic agent cardiotrast decreasing accumulation of the label by the kidneys. Acute CCl4 poisoning of the animals results in a sharp decrease in the liver capacity for accumulation of 131I-bilignost and to a slight rise in the preparation kidney level. Three-day administration of phenobarbital to rats produces a considerable drop in 125I-bilignost level in all the organs tested, suggesting an enhanced RCA excretion from the body.
在肝脏实验性病理状态下，研究了125I-和131I-必利胆醇在完整大鼠体内的分布动态。结果表明，胆囊造影剂必利胆醇主要被肝脏吸收和蓄积。这表明该制剂对肝脏具有选择性作用。给予125I-必利胆醇与未标记的胆囊造影剂必利胆醇和恩多瑞芬联合使用，会引起肝脏吸收的竞争，这使这些制剂与尿路造影剂卡迪造影剂有所不同，后者会减少肾脏对标记物的蓄积。动物急性四氯化碳中毒会导致肝脏蓄积131I-必利胆醇的能力急剧下降，而制剂在肾脏中的水平略有上升。给大鼠连续三天服用苯巴比妥会使所有测试器官中的125I-必利胆醇水平大幅下降，表明造影剂从体内的排泄增加。
